Your session is about to expire
← Back to Search
LDCT Lung Screening for Early Detection of Lung Cancer
N/A
Recruiting
Led By Daniel Carrizosa, MD
Research Sponsored by Daniel Carrizosa
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age 40-54 years at the time of consent.
Ability to read and understand the English and/or Spanish language.
Must not have
Known diagnosis of lung cancer in the past 5 years.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing whether lowering the minimum age for low-dose CT screening from 55 to 50 will decrease mortality in a high-risk population.
Who is the study for?
This trial is for people aged 40-54 who have a significant smoking history (at least 30 pack years), are currently smoking or quit within the last 15 years, and can understand English/Spanish. They must consent to share health information and follow study procedures. Those with past lung cancer diagnosis, CT scan contraindications, or pregnancy cannot join.
What is being tested?
The study tests if lowering the age for Low-dose Computed Tomography (LDCT) screening can help detect lung cancer earlier in smokers or recent quitters aged 40-54. This follows evidence that LDCT improves survival rates in older individuals.
What are the potential side effects?
While LDCT itself has minimal side effects, potential risks include exposure to low levels of radiation which may slightly increase the risk of developing cancer over one's lifetime.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 40 and 54 years old.
Select...
I can read and understand either English or Spanish.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I was diagnosed with lung cancer within the last 5 years.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Lung cancer diagnosis rate in individuals 40-54 years of age at their first screening (T0) with mobile low-dose CT.
Secondary study objectives
Impact of baseline demographic (including insurance status), socioeconomic, and healthcare-related factors on lung cancer rates and positive screening rates
Incidence rate of all types of cancer found with low-dose lung CT during lung cancer screening
Lung cancer diagnosis rate in individuals 40-54 years of age at subsequent screening visits (T1 and T2)
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment1 Intervention
Mobile Low-dose Computed Tomography (LDCT) Screening
Find a Location
Who is running the clinical trial?
Daniel CarrizosaLead Sponsor
Leon Levine FoundationUNKNOWN
Wake Forest University Health SciencesLead Sponsor
1,392 Previous Clinical Trials
2,451,702 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am between 40 and 54 years old.I have smoked for 30 or more years and quit less than 15 years ago, if at all.I can follow the study's procedures for its duration.I can read and understand either English or Spanish.I was diagnosed with lung cancer within the last 5 years.
Research Study Groups:
This trial has the following groups:- Group 1: Single Arm
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger